BioTuesdays’ Post

Leptomeningeal Metastases Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca: The Key Leptomeningeal Metastases Companies in the market include – Y-mAbs Therapeutics, Plus Therapeutics, AngioChem, AstraZeneca, and others.   The Leptomeningeal Metastases market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, … Continue reading → #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

Intrahepatic Cholangiocarcinoma Pipeline Update 2024: FDA Approvals, Therapeutic Advancements, and Key Companies involved by DelveInsight | Xencor, Relay Therapeutics, Kinnate Biopharma, Forma Therapy: Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, Intrahepatic Cholangiocarcinoma pipeline constitutes 20+ key companies continuously working towards developing 20+ Intrahepatic Cholangiocarcinoma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments … Continue reading → #Business #HealthMedicine #MarketingSales #PharmaceuticalsBiotech

Novartis is paying Monte Rosa Therapeutics $150M up front and up to $2.1B in milestones for exclusive global rights to develop, manufacture and commercialize a new class of drugs called "molecular glue degraders,” developed using Monte Rosa’s QuEEN platform. Among the candidates, Novartis will gain access to MRT-6160, for which Monte Rosa is currently conducting an early-stage study for immune-mediated conditions. Novartis will take over the development from mid-stage trials, with the goal to initiate Phase 2 trials next year. MRT-6160 may be applicable for various #autoimmune conditions including #ulcerativecolitis and #rheumatoidarthritis. The potential of molecular glue degraders can widen to other targets in cardiovascular disease and metabolism. 

Lisata Therapeutics, Inc. presentation by Dr. David J. Mazzo, Ph.D., President & CEO at the 10th Annual Oncology Innovation Forum Lisata Therapeutics is a clinical-stage pharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata’s lead product candidate, certepetide (formerly LSTA1), is an investigational drug designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to selectively target and penetrate solid tumors more effectively. Lisata has already established noteworthy commercial and R&D partnerships based on its CendR Platform® technology. The Company expects to announce numerous milestones over the next two years and believes that its projected capital will fund operations into early 2026, encompassing anticipated data milestones from its ongoing and planned clinical trials. View here: https://lnkd.in/dDkhmGte

https://lnkd.in/gPHf9ZC5 Key Insights: • Harpoon has created a range of innovative T-cell engagers utilizing the Tri-specific T cell Activating Construct (TriTAC®) platform • The TriTAC® platform is an engineered protein technology designed to guide a patient’s immune cells to eliminate tumor cells Visit MedicoInsights to explore key insights #HealthcareNews #drugs #StayInformed #MedicalNews #Harpoon #HealthTrends #Insights #HealthIndustry #HealthInnovation #merck #acquisition #agreement #HealthcareAnalytics #newsupdates  #msd #HealthcareNetworking #pharma #pharmaceuticals #pharmanews #pharmaindustry #pharmainnovation #update #medicoinsights

RMC-6291: Reprogramming a Molecular Glue to Target KRAS | https://lnkd.in/gY8BT6B2 -2023 Molecule of the Year Nominee (2//10)- Revolution Medicines' RMC-6291 works as a tri-complex inhibitor, forming a non-covalent binary complex with the abundant cytosolic protein, cyclophilin A. This RMC-6291:CypA binary complex then reversibly binds to KRAS, forming a non-covalent KRAS:RMC-6291:CypA tricomplex resulting in the irreversible inactivation of KRAS G12C. In contrast to existing KRAS inhibitors, which bind to KRAS in the non-signaling GDP-bound KRAS(OFF) state, the RMC-6291:CypA complex can engage KRAS in its signaling GTP-bound KRAS(ON) state, which could enable a greater rate, depth, and duration of response by preventing activity from resynthesized KRAS(ON). While an increasing number of follow-on KRAS inhibitors are emerging with similar mechanisms of action to Amgen's sotorasib or Mirati Therapeutics'/Bristol Myers Squibb's adagrasib, Revolution Medicines' RMC-6291 is representative of a completely novel approach that could become a strong addition to the clinical toolbox for KRAS, and serves as proof-of-concept for a new class of small molecule therapeutics entirely. Read the full article for a brief history of tri-complex inhibitors and their natural product origins, the evolution of molecules from hit to bRo5 leads, and why this program is a big deal both for patients and for the science of drug discovery. Article | https://lnkd.in/gY8BT6B2

Sionna and AbbVie deal can redefine cystic fibrosis therapeutics: GlobalData Sionna Therapeutics secures exclusive global rights to develop and commercialise advanced CF compounds, strengthening its pipeline and market position, reports GlobalData Sionna Therapeutics, a US-based clinical-stage life sciences company specialising in cystic fibrosis (CF), has secured exclusive global rights to develop and commercialise multiple advanced compounds through a licence agreement with AbbVie. This strategic acquisition includes Phase 2 compounds ABBV-2222 and ABBV-3067, and Phase 1 compound ABBV-2851, bolstering Sionna’s pipeline and its position in the CF market, says GlobalData. This partnership capitalises on AbbVie’s advanced research and Sionna’s innovative approach to CF therapy, specifically targeting the NBD1 domain of the CFTR protein. Sionna’s strategy aims to correct protein misfolding and instability at the molecular level, addressing the root causes of CF. AbbVie will receive an undisclosed upfront payment, equity investment in Sionna, and late-stage development and commercial milestones and royalties.

Eliem Therapeutics, a biotechnology company, completed the acquisition of Tenet Medicines, a development-stage private biotechnology company. Financial terms were not disclosed. “Today marks a transformative milestone for Eliem Therapeutics as we strive to become a leading immunology and inflammation company focused on developing novel treatments for a broad range of autoimmune diseases. With the concurrent close of our $120m private placement, we now have a robust balance sheet with approximately $220m in cash and cash equivalents and are poised to advance the development of TNT119, our lead anti-CD19 antibody, through multiple milestones and for several autoimmune diseases. We look forward to initiating Phase 2 clinical trials of TNT119 later this year," Andrew Levin, Eliem Executive Chairman. Tenet Medicines (led by Stephen Thomas and William Bonificio) was advised by Cooley LLP (led by Ryan Sansom). Eliem Therapeutics (led by William Bonificio) was advised by Leerink Partners, WilmerHale and ICR Westwicke (led by Christopher Brinzey). #MergersAcquisitionsDivestitures #Healthcare #Biotechnology

Weekly Market News! 💊 Sanofi, BioNTech, BMS, Surrozen, J&J, FTC, Merck KGaA, and Lindus have all been in the news this week. Sanofi has begun a full pipeline reprioritization with layoffs, while BioNTech's cancer vaccine has shown a 3-year immune response. BMS's schizophrenia drug has demonstrated long-term benefits, and Surrozen's Wnt mimetic antibody has proven effective in mice with lung fibrosis. J&J has added shockwave to its cardio collection with a $13.1B deal, and the FTC has requested more information on Boston Scientific and Axonics' $3.7B deal. Merck KGaA has signed a $1.4B biobuck ADC deal with Caris, and Lindus has launched an all-in-one CRO for respiratory trials. Stay informed on the latest news in the pharmaceutical industry. #pharmaceuticals #biotech #healthcare #news

In business news,  Merck, known as MSD outside of the United States and Canada, announced the completion of the acquisition of Eyebiotech Limited. EyeBio is now a wholly-owned subsidiary of Merck. EyeBio’s lead candidate, Restoret™ (EYE103), is an investigational, potentially first-in-class tetravalent, tri-specific antibody that acts as an agonist of the Wingless-related integration site (Wnt) signaling pathway. Based on positive results from the open-label Phase 1b/2a AMARONE study in patients with diabetic macular edema and neovascular age-related macular degeneration, Restoret is scheduled to advance into a pivotal Phase 2b/3 trial to evaluate its potential for the treatment of patients with DME in the second half of 2024. https://lnkd.in/eRdnnxBZ